Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
samuraciclib + elacestrant
- Development stage
- Unknown
- Lead developer
- Carrick Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Samuraciclib + elacestrant is an investigational combination therapy being developed by Carrick Therapeutics in collaboration with the Menarini Group. It consists of samuraciclib (CT7001), a small-molecule inhibitor of cyclin-dependent kinase 7 (CDK7), and elacestrant (Orserdu), an oral selective estrogen receptor degrader (SERD). The combination is primarily targeted at patients with hormone receptor-positive (HR+), HER2-negative metastatic or locally advanced breast cancer who have progressed on prior CDK4/6 inhibitor therapy. By inhibiting CDK7, samuraciclib disrupts the transcriptional machinery and cell cycle progression, while elacestrant degrades the estrogen receptor, providing a dual-pathway blockade to overcome endocrine resistance.
- Other names
- CT7001 + Orserdusamuraciclib + OrserduSUMIT-ELA
02
Targets
CDK7CDK1 (Cyclin-dependent kinase 1)ESR2 (ERβ)CDK2 (Cyclin-dependent kinase 2)ESR1 (ERα)CDK9 (Cyclin-dependent kinase 9)CDK5 (Cyclin-dependent kinase 5)
Beyond the preview
Go deeper on samuraciclib + elacestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on samuraciclib + elacestrant.